A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.

@article{Pflugfelder2004ARD,
  title={A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.},
  author={Stephen Carl Pflugfelder and Steven L Maskin and Bruce Anderson and James Chodosh and Edward J. Holland and Cintia S de Paiva and Stephen P. Bartels and Teresa Micuda and Howard M Proskin and Roger Vogel},
  journal={American journal of ophthalmology},
  year={2004},
  volume={138 3},
  pages={444-57}
}
PURPOSE To evaluate loteprednol etabonate ophthalmic 0.5% suspension, versus placebo for treatment of the inflammatory component of keratoconjunctivitis sicca in patients with delayed tear clearance. DESIGN Randomized, double-masked, placebo-controlled clinical trial. METHODS Sixty-four patients with keratoconjunctivitis sicca and delayed tear clearance were randomly assigned to receive either loteprednol or vehicle 4 times a day for 4 weeks. Patients were evaluated at weeks 2 and 4 of… CONTINUE READING
61 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

Similar Papers

Loading similar papers…